The Problem With Tradition

Origins (1920s-1960s): - Thomas Addis’s rat experiments → high protein damages kidneys - Uncontrolled case series → established protein restriction as “standard” - Critical issue: Minimal human evidence; tradition persisted 100+ years

The MDRD Study (1994): - Largest RCT ever conducted (840 patients) - Primary result: NO significant benefit (p=0.22 moderate CKD; p=0.07 advanced CKD) - What happened? Secondary analyses emphasized exploratory findings; primary null result downplayed - Long-term follow-up (2009): Very low-protein diet associated with 92% increased mortality (HR 1.92)

Current Guideline Paradox

Clinical Pearl: Different experts reach opposite conclusions from overlapping evidence—classic sign of weak evidence base.

Systematic Reviews & Meta-Analyses

The Problem With MDRD Study Interpretation

Study Design: - Cohort A: eGFR 25-55, randomized to 1.3 vs 0.58 g/kg/day - Cohort B: eGFR 13-24, randomized to 0.58 vs 0.28 g/kg/day (with ketoanalogs) - Duration: 3 years (short by modern standards)

Primary Results: - Cohort A: No significant difference in GFR decline - Cohort B: Marginally slower decline (p=0.066) — not statistically significant

What Followed: - ✗ 50+ secondary analyses published (selective reporting bias) - ✗ “Achieved protein intake” analyses (converted RCT to observational study) - ✓ Guidelines cited secondary findings over primary null result - ✗ Long-term follow-up (16 years) showed excess mortality with VLPD

Clinical Lesson: Beware guidelines that emphasize exploratory analyses while downplaying negative primary results.

Protein-Energy Wasting (PEW): Definition & Prevalence

Definition (ISRNM 2008): Decreased body protein and energy stores; requires ≥3 of 4 categories: 1. Biochemical: Albumin <38 g/L, transthyretin <0.3 g/L, cholesterol <2.6 mmol/L 2. Low body mass: BMI <23 kg/m², unintentional weight loss >5% in 3 months, body fat <10% 3. Reduced muscle: Low mid-arm circumference, sarcopenia (imaging/function) 4. Low dietary intake: <0.60 g/kg/day protein (CKD) or <0.80 g/kg/day (dialysis)

Prevalence by CKD Stage

Key Point: PEW is one of the strongest mortality predictors in CKD—stronger than eGFR or albuminuria.

Sarcopenia in CKD: Why It Occurs

Multiple overlapping mechanisms:

1. Uremic Toxins: Indoxyl sulfate activates ubiquitin-proteasome system (muscle protein degradation pathway)

2. Metabolic Acidosis: Even mild acidosis stimulates muscle catabolism via:

   • Glucocorticoid-dependent pathways
   • Branched-chain amino acid oxidation

3. Hormonal Derangements:

   • Insulin resistance (protein degradation activated)
   • ↓ IGF-1 (anabolic hormone deficiency)
   • ↑ PTH (catabolic stimulus)
   • ↓ Testosterone in men (muscle-building hormone)

4. Chronic Inflammation: TNF-α, IL-6, IL-1 activate muscle protein degradation

5. Physical Inactivity: Common in advanced CKD patients

Important: Protein restriction ADDS to this catabolic burden.

Sarcopenia Prevalence & Clinical Impact

Epidemiology: - 24% of CKD stages 3b-5 patients have sarcopenia (EWGSOP2 criteria) - Strong association with malnutrition (52% sarcopenic vs 20% non-sarcopenic have PEW) - NOT strongly correlated with inflammation—nutritional factors predominate

The Protein Paradox: KNOW-CKD Study

Korean CKD cohort followed 3 years: - Highest protein intake quintile: Lost ~40% LESS lean muscle mass - Lowest protein intake quintile: Greater muscle loss despite “sparing” protein - Interpretation: Adequate protein intake protects muscle despite CKD

Older Adults With CKD: New Evidence Contradicts Restriction

Children: No Restriction Allowed

KDIGO 2024 Practice Point: - ✗ Do NOT restrict protein in children - ✓ Target upper end of normal range for healthy children - Rationale: Growth requirements; protein restriction impairs linear growth and development

Diabetic Kidney Disease: Limited Evidence for Restriction

Current approach: - More conservative targets (0.6-0.8 g/kg/day if restricted) - Evidence weaker than non-diabetic CKD - May worsen glycemic control if too restrictive - Consider individual risk assessment

Patients With Existing PEW or Low BMI: Avoid Restriction

Contraindications to protein restriction: - BMI <23 kg/m² - Recent unintentional weight loss >5% - Low serum albumin (<3.5 g/dL) - Low grip strength - Any signs of nutritional compromise

Appropriate Candidates (Stage 4-5 CKD)

Strict criteria required: - ✓ CKD stage G4-G5 (eGFR <30) - ✓ High near-term ESKD risk - ✓ Younger age (<65 with good baseline nutrition) - ✓ No sarcopenia/frailty - ✓ Access to regular dietitian follow-up - ✓ Motivated, capable of dietary adherence - ✓ Adequate baseline nutritional status

Very Low Protein With Ketoanalogs (Most Restrictive Approach)

Potential benefit: 35% reduction in kidney failure progression in advanced CKD

Requires: - 0.28-0.43 g/kg protein + ketoanalogs to achieve 0.55-0.60 g/kg equivalent - Monthly dietary assessments initially - Bimonthly physician visits - Careful albumin/nutritional monitoring - High cost and pill burden

Realistic adherence: <20% of patients sustain long-term

SGLT2 Inhibitors

GLP-1 Receptor Agonists (Semaglutide, FLOW Trial)

Bottom Line on Modern Therapy vs Dietary Restriction

SGLT2i + GLP-1 RA provide: - Larger kidney protection than protein restriction - Mortality benefits (protein restriction shows none) - Better tolerability - Additive mechanisms when combined with RAAS blockade

Implication: Protein restriction becomes questionable as primary intervention when superior pharmacotherapy available.

Step 1: Patient Selection & Counseling

• Confirm stage 4-5 CKD with high ESKD risk
• Verify absence of sarcopenia/malnutrition markers
• Detailed discussion of expectations, monitoring burden
• Written dietary guidelines with meal examples

Step 2: Establish Target Protein Intake

Step 3: Emphasize ENERGY INTAKE

Critical: Adequate calories prevent negative nitrogen balance - Target: 30-35 kcal/kg/day - Example: 70 kg person needs 2100-2450 kcal/day - Quality protein: Complete proteins with all essential amino acids - Lean meats, fish, eggs, dairy, soy, legumes - Avoid very high-fat sources (saturated fat increases CV risk)

Step 4: Regular Monitoring

At least quarterly assessments: - Anthropometrics: Weight, BMI, mid-arm circumference (track trends) - Biochemistry: Albumin, prealbumin, total cholesterol - Dietary assessment: 24-hour recall or food frequency questionnaire - Functional: Handgrip strength, gait speed, self-reported energy - Labs: eGFR, K⁺, phosphorus, calcium

Step 5: Multidisciplinary Team

• Registered Dietitian: Meal planning, food substitutions, education
• Nephrologist: Monitor kidney function, medication adjustments
• Pharmacist: Drug-nutrient interactions, supplement counseling
• Social Worker: Food access, financial barriers, social support

Step 6: Discontinue If Problems Emerge

Red flags requiring cessation: - Weight loss >5% unintended - Albumin declining - Grip strength declining - Increased hospitalizations - Patient unable to maintain diet

Clearly Evidence-Based

✓ No protein restriction in children — proven growth impairment (high-quality RCTs)

✓ Avoid very high protein (>1.3 g/kg/day) — observational evidence of accelerated progression

✓ Monitor nutritional status during any intervention — established clinical standard

✓ Prioritize pharmacotherapy (SGLT2i, GLP-1 RA) — superior kidney outcomes + mortality benefits

Moderately Evidence-Based

~ VLPD (0.3-0.4 g/kg/day with ketoanalogs) in carefully selected G4-G5 CKD — RCT support but limited applicability + safety concerns

Plant-based protein sources — emerging mechanistic data suggesting additional benefits

Primarily Eminence-Based (Tradition, Not Evidence)

✗ Universal protein restriction (0.55-0.60 g/kg/day) in G3-G5 — weak evidence, secondary analyses misrepresented, contradicted by long-term mortality data

✗ KDOQI Grade 1A recommendation — dramatically overstates evidence quality (only 13% of recommendations truly warrant 1A)

✗ Routine restriction in elderly CKD — contradicted by recent mortality studies

✗ Protein restriction in DKD — minimal specific evidence, may worsen glucose control

Older Adults: Rethink Restriction

Problem: Age-related sarcopenia + CKD catabolism + dietary restriction = triple threat

Solution: Higher protein targets (1.0-1.2 g/kg), strength training, close monitoring

Evidence: Recent mortality data favor higher protein in this population

Patients with Sarcopenia: Prioritize Muscle

Diagnosis: EWGSOP2 criteria (low muscle mass + low strength/function)

Management: - Adequate protein (≥0.8 g/kg minimum) - Resistance exercise (critical) - Consider testosterone replacement in men (controversial but evidence growing) - Consider oral nutritional supplements (whey protein, amino acids)

Dialysis-Dependent CKD (G5D): Different Rules

Protein targets INCREASE on dialysis: - Pre-dialysis: 0.55-0.60 g/kg - Post-dialysis initiation: 1.2-1.3 g/kg (compensate for dialytic losses)

Rationale: Dialysis removes amino acids and proteins; higher intake needed to maintain balance

Related Student Handouts

• CKD Overview and Classification
• CKD Complications
• Diabetic Kidney Disease
• Calcium and Phosphorus Disorders

Clinical Content (01-Clinical-Medicine/Nephrology)

• CKD Hub - Full Clinical Reference
• Essential Renal Laboratory Tests

Butler-COM Resources

• Butler COM - Nephrology Deep Dive